{"id":21871,"date":"2026-02-28T20:34:56","date_gmt":"2026-02-28T20:34:56","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/21871\/"},"modified":"2026-02-28T20:34:56","modified_gmt":"2026-02-28T20:34:56","slug":"biontechs-breast-cancer-adc-outperforms-roches-kadcyla","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/21871\/","title":{"rendered":"BioNTech\u2018s breast cancer ADC outperforms Roche&#8217;s Kadcyla"},"content":{"rendered":"<p><a href=\"https:\/\/european-biotechnology.com\/latest-news\/german-chinese-adc-collaboration\/\" rel=\"nofollow noopener\" target=\"_blank\">BioNTech\u2019s\/Duality Biologics\u2019<\/a> Phase III pivotal study of trastuzumab pamirtecan (BNT323\/DB-1303) compared the safety and efficacy of the ADCs with Roche\u2019s <a href=\"https:\/\/european-biotechnology.com\/latest-news\/phase-iii-success-for-roche-breast-cancer-drug\/\" rel=\"nofollow noopener\" target=\"_blank\">Kadcyla<\/a>, which carry the same HER2 antibody but different payloads. However, it also competes with Enhertu, which also uses a topoisomerase I payload (camptothecin derivative) and is marketed in Japan by Daiichi Sankyo and in collaboration with AstraZeneca in the rest of the world.<\/p>\n<p>According to interim results of a Phase III study of BioNTech\/Duality Biologics, trastuzumab pamirtecan performed better than Roche\u2019s T-DM1 ADC, which is equipped with a non-cleavable thio-linker and the first-generation payload Maytansinoid DM1, in terms of the surrogate marker progression-free survival (PFS). and achieved a median PFS of 9.6 months in registration studies. It is not yet known whether BioNTech\/Dual Biologics ADC was below or above the median PFS of 28.8 (DESTINY-Breast03 study) and 13.2 months (Low HER2, DESTINY-Breast06 study) achieved by Daiichi\u2019s ADC Enhertu, as no data has been published by BioNTech to date. Trastuzumab pamirtecan shows strong bystander activity due to good membrane permeability, also a cleavable linker and a topoisomerase I payload.<\/p>\n<p>However, as Roche\u2019s Kadcyla, which is approved for metastatic breast cancer and as an neoadjuvant treatment, has recently seen strong growth in China in the adjuvant setting, BioNTech\u2019s results pose a threat to Kadcyla\u2019s global breast cancer sales of nearly US$2 billion. This is becauseBIONTech\u2019s licencor Duality Biologics now intends to apply for marketing approval for trastuzumab pamirtecan in China.<\/p>\n<p>As part of the head-to-head study with Roche\u2019s Kadcyla, Duality Biologics recruited 228 breast cancer patients who had previously received chemotherapy and Roche\u2019s anti-HER2 antibody trastuzumab (Herceptin).<\/p>\n","protected":false},"excerpt":{"rendered":"BioNTech\u2019s\/Duality Biologics\u2019 Phase III pivotal study of trastuzumab pamirtecan (BNT323\/DB-1303) compared the safety and efficacy of the ADCs&hellip;\n","protected":false},"author":2,"featured_media":21872,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[14293,14294,207,134],"class_list":["post-21871","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-adcs","tag-astrazeneca-and-daiichi-sankyo","tag-breast-cancer","tag-roche"],"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/21871","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=21871"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/21871\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/21872"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=21871"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=21871"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=21871"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}